Compare AOSL & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AOSL | FBRX |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 919.1M | 899.4M |
| IPO Year | 2007 | 2017 |
| Metric | AOSL | FBRX |
|---|---|---|
| Price | $32.06 | $76.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $24.00 | ★ $67.00 |
| AVG Volume (30 Days) | 634.0K | ★ 2.0M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.30 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $342,291,000.00 | $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.41 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.01 | $9.25 |
| 52 Week High | $54.34 | $77.20 |
| Indicator | AOSL | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.47 | 84.70 |
| Support Level | $19.24 | $24.72 |
| Resistance Level | $46.93 | N/A |
| Average True Range (ATR) | 2.52 | 3.80 |
| MACD | -0.03 | 2.61 |
| Stochastic Oscillator | 47.71 | 98.30 |
Alpha & Omega Semiconductor Ltd designs, develops and supplies a portfolio of power semiconductors targeting various applications, including personal computers, flat-panel TVs, LED lighting, smartphones, battery packs, consumer and industrial motor controls and power supplies for TVs, computers, servers and telecommunications equipment. It generates revenue mainly from the sale of power semiconductors, consisting of power discretes and power ICs with a presence in Hong Kong, China, South Korea, the United States and other countries. It operates in one operating segment: the design, development and supply of power semiconductor products for computing, consumer electronics, communication and industrial applications.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.